Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun-Sheng Wang

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Materials Science & Engineering. C, Materials for Biological Applications|March 25, 2020
Biodegradable polymer-nanoclay composites as intestinal sleeve implants installed in digestive tract for obesity and type 2 diabetes treatmentWei-Hsin Hsu, Hao-Ming Chang, Ya-Lun Lee, et al.
Clinical Pharmacokinetics|September 29, 2012
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjectsRandy Dockens, Jun-Sheng Wang, Lorna Castaneda, et al.
Clinical Drug Investigation|September 29, 2012
Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young menGary Tong, Lorna Castaneda, Jun-Sheng Wang, et al.
International Journal of Biological Macromolecules|May 29, 2026
Surface-engineered heparin- and methoxy poly(ethylene glycol)-modified gelatin microspheres for enhanced extracellular vesicle enrichmentYu-Ting Tai, Yu-Ting Cheng, Ding-An Li, et al.
British Journal of Clinical Pharmacology|May 24, 2012
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestatGary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, et al.
Clinical Therapeutics|March 3, 2012
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markersGary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, et al.
American Journal of Human Genetics|May 20, 2008
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basisHao-Jie Zhu, Kennerly S Patrick, Hong-Jie Yuan, et al.
ACS Applied Materials & Interfaces|January 20, 2026
Enhanced Fuel Cell Performance with Robust Pyridinium-Derivative-Functionalized SBS Triblock Copolymer Anion-Exchange MembranesBeyadgalem Endawoke Anley, Yohannis Wondwosen Ahmed, Afandi Yusuf, et al.
BMC Medicine|December 9, 2022
A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinomaNing Li, Tao Wu, Yong-Gui Hong, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|April 4, 2022
Improvement in the Blood Urea Nitrogen and Serum Creatinine Using New Cultivation of <i>Cordyceps militaris</i>Chih-Hui Yang, Wen-Shuo Kuo, Jun-Sheng Wang, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Materials Science & Engineering. C, Materials for Biological Applications|March 25, 2020
Biodegradable polymer-nanoclay composites as intestinal sleeve implants installed in digestive tract for obesity and type 2 diabetes treatmentWei-Hsin Hsu, Hao-Ming Chang, Ya-Lun Lee, et al.
Clinical Pharmacokinetics|September 29, 2012
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjectsRandy Dockens, Jun-Sheng Wang, Lorna Castaneda, et al.
Clinical Drug Investigation|September 29, 2012
Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young menGary Tong, Lorna Castaneda, Jun-Sheng Wang, et al.
International Journal of Biological Macromolecules|May 29, 2026
Surface-engineered heparin- and methoxy poly(ethylene glycol)-modified gelatin microspheres for enhanced extracellular vesicle enrichmentYu-Ting Tai, Yu-Ting Cheng, Ding-An Li, et al.
British Journal of Clinical Pharmacology|May 24, 2012
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestatGary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, et al.
Clinical Therapeutics|March 3, 2012
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markersGary Tong, Jun-Sheng Wang, Oleksandr Sverdlov, et al.
American Journal of Human Genetics|May 20, 2008
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basisHao-Jie Zhu, Kennerly S Patrick, Hong-Jie Yuan, et al.
ACS Applied Materials & Interfaces|January 20, 2026
Enhanced Fuel Cell Performance with Robust Pyridinium-Derivative-Functionalized SBS Triblock Copolymer Anion-Exchange MembranesBeyadgalem Endawoke Anley, Yohannis Wondwosen Ahmed, Afandi Yusuf, et al.
BMC Medicine|December 9, 2022
A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinomaNing Li, Tao Wu, Yong-Gui Hong, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|April 4, 2022
Improvement in the Blood Urea Nitrogen and Serum Creatinine Using New Cultivation of <i>Cordyceps militaris</i>Chih-Hui Yang, Wen-Shuo Kuo, Jun-Sheng Wang, et al.
Pageof 8